Pediatric leukemia predisposition syndromes: Clues to understanding leukemogenesis

Cancer Genetics

Volumn 204, Issue 5, 2011, Pages 227-244

  Seif, Alix E ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Leukemia; Pediatric; Predisposition; Syndrome

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEUPLOIDY; ATAXIA TELANGIECTASIA; BLOOM SYNDROME; CANCER SUSCEPTIBILITY; CARDIOTOXICITY; CELL CYCLE; CELL DIFFERENTIATION; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; DOWN SYNDROME; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; FANCONI ANEMIA; GENETIC PREDISPOSITION; HUMAN; INFECTION; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NEUROFIBROMATOSIS; NIJMEGEN BREAKAGE SYNDROME; NONHODGKIN LYMPHOMA; NOONAN SYNDROME; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVIEW; SEVERE CONGENITAL NEUTROPENIA; THROMBOCYTE DISORDER; DISORDERS OF DNA SYNTHESIS AND REPAIR; EPIDEMIOLOGY; GENETICS; LEUKEMIA; NEUTROPENIA;

ATAXIA TELANGIECTASIA;

CAUSALITY; CELL CYCLE; CELL DIFFERENTIATION; DNA REPAIR-DEFICIENCY DISORDERS; DOWN SYNDROME; GENETIC PREDISPOSITION TO DISEASE; LEUKEMIA; NEUROFIBROMATOSIS 1; NEUTROPENIA; NOONAN SYNDROME;

EID: 80051590706     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.04.005     Document Type: Review

References (238)

1. Baer C.F., Miyamoto M.M., Denver D.R. Mutation rate variation in multicellular eukaryotes: causes and consequences. Nat Rev Genet 2007, 8:619-631.
2. Camenisch U., Naegeli H. Role of DNA repair in the protection against genotoxic stress. EXS 2009, 99:111-150.
3. Lopez-Camarillo C., Lopez-Casamichana M., Weber C., et al. DNA repair mechanisms in eukaryotes: special focus in Entamoeba histolytica and related protozoan parasites. Infect Genet Evol 2009, 9:1051-1056.
4. Moldovan G.L., D'Andrea A.D. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009, 43:223-249.
5. Darzynkiewicz Z., Traganos F., Wlodkowic D. Impaired DNA damage response-an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. Eur J Pharmacol 2009, 625:143-150.
6. Rubin P., Williams J.P., Devesa S.S., et al. Cancer genesis across the age spectrum: associations with tissue development, maintenance, and senescence. Semin Radiat Oncol 2010, 20:3-11.
7. Alter B.P. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program 2007, 29-39.
8. D'Andrea A.D. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010, 362:1909-1919.
9. Shimamura A., Alter B.P. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Reviews 2010, 24:101-122.
10. Lindor N.M., Greene M.H. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998, 90:1039-1071.
11. Kutler D.I., Singh B., Satagopan J., et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003, 101:1249-1256.
12. Alter B.P. Fanconi's anemia and malignancies. Am J Hematol 1996, 53:99-110.
13. Alter B.P., Greene M.H., Velazquez I., et al. Cancer in Fanconi anemia. Blood 2003, 101:2072.
14. Rosenberg P.S., Alter B.P., Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica 2008, 93:511-517.
15. Gyger M., Perreault C., Belanger R., et al. Unsuspected Fanconi's anemia and bone marrow transplantation in cases of acute myelomonocytic leukemia. N Engl J Med 1989, 321:120-121.
16. Vaz F., Hanenberg H., Schuster B., et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010, 42:406-409.
17. Stoepker C., Hain K., Schuster B., et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011, 43:138-141.
18. Alter B.P., Rosenberg P.S., Brody L.C. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. Journal of Medical Genetics 2007, 44:1-9.
19. Hirsch B., Shimamura A., Moreau L., et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 2004, 103:2554-2559.
20. Neveling K., Endt D., Hoehn H., et al. Genotype-phenotype correlations in Fanconi anemia. Mutat Res 2009, 668:73-91.
21. Alter B.P., Joenje H., Oostra A.B., et al. Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. Arch Otolaryngol Head Neck Surg 2005, 131:635-639.
22. Gross M., Hanenberg H., Lobitz S., et al. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res 2002, 98:126-135.
23. Lo Ten Foe J.R., Kwee M.L., Rooimans M.A., et al. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet 1997, 5:137-148.
24. Waisfisz Q., Morgan N.V., Savino M., et al. Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat Genet 1999, 22:379-383.
25. D'Andrea A.D., Dahl N., Guinan E.C., et al. Marrow failure. Hematology Am Soc Hematol Educ Program 2002, 58-72.
26. Mehta P.A., Ileri T., Harris R.E., et al. Chemotherapy for myeloid malignancy in children with Fanconi anemia. Pediatr Blood Cancer 2007, 48:668-672.
27. Myers K.C., Davies S.M. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant 2009, 15:279-292.
28. Tan P.L., Wagner J.E., Auerbach A.D., et al. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatr Blood Cancer 2006, 46:630-636.
29. Ayas M., Al-Jefri A., Al-Mahr M., et al. Allogeneic stem cell transplantation in patients with Fanconi's anemia and myelodysplasia or leukemia utilizing low-dose cyclophosphamide and total body irradiation. Bone Marrow Transplant 2004, 33:15-17.
30. Chaudhury S., Auerbach A.D., Kernan N.A., et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol 2008, 140:644-655.
31. Kelly P.F., Radtke S., von Kalle C., et al. Stem cell collection and gene transfer in Fanconi anemia. Mol Ther 2007, 15:211-219.
32. Chun H.H., Gatti R.A. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004, 3:1187-1196.
33. Matei I.R., Guidos C.J., Danska J.S. ATM-dependent DNA damage surveillance in T-cell development and leukemogenesis: the DSB connection. Immunol Rev 2006, 209:142-158.
34. Gatti R. Ataxia-telangiectasia. GeneReviews, 1993-. Available at: . Accessed on April 13, 2011. http://www.ncbi.nlm.nih.gov/books/NBK26468/.
35. Crawford T.O., Skolasky R.L., Fernandez R., et al. Survival probability in ataxia telangiectasia. Arch Dis Child 2006, 91:610-611.
36. Morrell D., Cromartie E., Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986, 77:89-92.
37. Olsen J.H., Hahnemann J.M., Borresen-Dale A.L., et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst 2001, 93:121-127.
38. Taylor A.M., Metcalfe J.A., Thick J., et al. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996, 87:423-438.
39. Ziino O., Rondelli R., Micalizzi C., et al. Acute lymphoblastic leukemia in children with associated genetic conditions other than Down's syndrome. The AIEOP experience. Haematologica 2006, 91:139-140.
40. Gumy-Pause F., Wacker P., Maillet P., et al. ATM promoter analysis in childhood lymphoid malignancies: a brief communication. Leuk Res 2006, 30:335-337.
41. Murphy R.C., Berdon W.E., Ruzal-Shapiro C., et al. Malignancies in pediatric patients with ataxia telangiectasia. Pediatr Radiol 1999, 29:225-230.
42. Lin C.H., Lin W.C., Wang C.H., et al. Child with ataxia telangiectasia developing acute myeloid leukemia. J Clin Oncol 2010, 28:e213-e214.
43. Viniou N., Terpos E., Rombos J., et al. Acute myeloid leukemia in a patient with ataxia-telangiectasia: a case report and review of the literature. Leukemia 2001, 15:1668-1670.
44. Lavin M.F. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008, 9:759-769.
45. Stagni V., di Bari M.G., Cursi S., et al. ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells. Blood 2008, 111:829-837.
46. Roos J., Hennig I., Schwaller J., et al. Expression of TCL1 in hematologic disorders. Pathobiology 2001, 69:59-66.
47. Stray-Pedersen A., Borresen-Dale A.L., Paus E., et al. Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol 2007, 11:375-380.
48. Lavin M.F., Gueven N., Bottle S., et al. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull 2007, 81-82:129-147.
49. Sun X., Becker-Catania S.G., Chun H.H., et al. Early diagnosis of ataxia-telangiectasia using radiosensitivity testing. J Pediatr 2002, 140:724-731.
50. Honda M., Takagi M., Chessa L., et al. Rapid diagnosis of ataxia-telangiectasia by flow cytometric monitoring of DNA damage-dependent ATM phosphorylation. Leukemia 2009, 23:409-414.
51. Nahas S.A., Butch A.W., Du L., et al. Rapid flow cytometry-based structural maintenance of chromosomes 1 (SMC1) phosphorylation assay for identification of ataxia-telangiectasia homozygotes and heterozygotes. Clin Chem 2009, 55:463-472.
52. Porcedda P., Turinetto V., Brusco A., et al. A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry A 2008, 73:508-516.
53. Toledano S.R., Lange B.J. Ataxia-telangiectasia and acute lymphoblastic leukemia. Cancer 1980, 45:1675-1678.
54. Chen R.L., Wang P.J., Hsu Y.H., et al. Severe lung fibrosis after chemotherapy in a child with ataxia-telangiectasia. J Pediatr Hematol Oncol 2002, 24:77-79.
55. Sandoval C., Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol 1998, 31:491-497.
56. Eyre J.A., Gardner-Medwin D., Summerfield G.P. Leukoencephalopathy after prophylactic radiation for leukaemia in ataxia telangiectasia. Arch Dis Child 1988, 63:1079-1080.
57. Yanofsky R.A., Seshia S.S., Dawson A.J., et al. Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment. Can J Neurol Sci 2009, 36:462-467.
58. Seidemann K., Henze G., Beck J.D., et al. Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol 2000, 11(Suppl 1):141-145.
59. Chrzanowska K.H., Piekutowska-Abramczuk D., Popowska E., et al. Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies. Int J Cancer 2006, 118:1269-1274.
60. Varon R., Vissinga C., Platzer M., et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 1998, 93:467-476.
61. Resnick I.B., Kondratenko I., Togoev O., et al. Nijmegen breakage syndrome: clinical characteristics and mutation analysis in eight unrelated Russian families. J Pediatr 2002, 140:355-361.
62. Nijmegen breakage syndrome. Arch Dis Child 2000, 82:400-406. The International Nijmegen Breakage Syndrome Study Group.
63. Digweed M., Sperling K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 2004, 3:1207-1217.
64. Gladkowska-Dura M., Dzierzanowska-Fangrat K., Dura W.T., et al. Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation. J Pathol 2008, 216:337-344.
65. Van de Kaa C.A., Weemaes C.M., Wesseling P., et al. Postmortem findings in the Nijmegen breakage syndrome. Pediatr Pathol 1994, 14:787-796.
66. Demuth I., Digweed M. The clinical manifestation of a defective response to DNA double-strand breaks as exemplified by Nijmegen breakage syndrome. Oncogene 2007, 26:7792-7798.
67. Varon R., Reis A., Henze G., et al. Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res 2001, 61:3570-3572.
68. di Masi A., Antoccia A. NBS1 Heterozygosity and Cancer Risk. Curr Genomics 2008, 9:275-281.
69. Helmink B.A., Bredemeyer A.L., Lee B.S., et al. MRN complex function in the repair of chromosomal Rag-mediated DNA double-strand breaks. J Exp Med 2009, 206:669-679.
70. van der Burg M., Pac M., Berkowska M.A., et al. Loss of juxtaposition of RAG-induced immunoglobulin DNA ends is implicated in the precursor B-cell differentiation defect in NBS patients. Blood 2010, 115:4770-4777.
71. Zhang Y., Zhou J., Lim C.U. The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control. Cell Res 2006, 16:45-54.
72. Concannon PJ, Gatti RA. Nijmegen breakage syndrome. GeneReviews, 1999-. Available at: . Accessed on March 20, 2011. http://www.ncbi.nlm.nih.gov/books/NBK1176/.
73. van der Burgt I., Chrzanowska K.H., Smeets D., et al. Nijmegen breakage syndrome. J Med Genet 1996, 33:153-156.
74. Dembowska-Baginska B., Perek D., Brozyna A., et al. Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). Pediatr Blood Cancer 2009, 52:186-190.
75. Albert M.H., Gennery A.R., Greil J., et al. Successful SCT for Nijmegen breakage syndrome. Bone Marrow Transplant 2010, 45:622-626.
76. Bohr V.A. Rising from the RecQ-age: the role of human RecQ helicases in genome maintenance. Trends Biochem Sci 2008, 33:609-620.
77. German J. Bloom syndrome: a mendelian prototype of somatic mutational disease. Medicine (Baltimore) 1993, 72:393-406.
78. German J. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 1997, 93:100-106.
79. Hutteroth T.H., Litwin S.D., German J. Abnormal immune responses of Bloom's syndrome lymphocytes in vitro. J Clin Invest 1975, 56:1-7.
80. Jain D., Hui P., McNamara J., et al. Bloom syndrome in sibs: first reports of hepatocellular carcinoma and Wilms tumor with documented anaplasia and nephrogenic rests. Pediatr Dev Pathol 2001, 4:585-589.
81. Sanz MM, German J. Bloom's syndrome. GeneReviews, 1993-. Available at: . Accessed on March 12, 2011. http://www.ncbi.nlm.nih.gov/books/NBK1398.
82. German J., Sanz M.M., Ciocci S., et al. Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum Mutat 2007, 28:743-753.
83. Barakat A., Ababou M., Onclercq R., et al. Identification of a novel BLM missense mutation (2706T>C) in a Moroccan patient with Bloom's syndrome. Hum Mutat 2000, 15:584-585.
84. Dutertre S., Ababou M., Onclercq R., et al. Cell cycle regulation of the endogenous wild type Bloom's syndrome DNA helicase. Oncogene 2000, 19:2731-2738.
85. Poppe B., Van Limbergen H., Van Roy N., et al. Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genet Cytogenet 2001, 128:39-42.
86. Cleary S.P., Zhang W., Di Nicola N., et al. Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Res 2003, 63:1769-1771.
87. Broberg K., Huynh E., Schlawicke Engstrom K., et al. Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. BMC Cancer 2009, 9:140.
88. Straughen J., Ciocci S., Ye T.Z., et al. Physical mapping of the bloom syndrome region by the identification of YAC and P1 clones from human chromosome 15 band q26.1. Genomics 1996, 35:118-128.
89. Wu L. Role of the BLM helicase in replication fork management. DNA Repair (Amst) 2007, 6:936-944.
90. German J., Schonberg S., Louie E., et al. Bloom's syndrome. IV. Sister-chromatid exchanges in lymphocytes. Am J Hum Genet 1977, 29:248-255.
91. German J. Bloom's syndrome: incidence, age of onset, and types of leukemia in the Bloom's syndrome registry. Genetics of Hematological Disorders 1992, 241-258. Hemisphere, Washington, DC. C.S. Batrtsocas, D. Loukopoulos (Eds.).
92. Whittingham S., Pitt D.B., Sharma D.L., et al. Stress deficiency of the T-lymphocyte system exemplified by Down syndrome. Lancet 1977, 1:163-166.
93. Pasmant E., Ballerini P., Lapillonne H., et al. SPRED1 disorder and predisposition to leukemia in children. Blood 2009, 114:1131.
94. Tidyman W.E., Rauen K.A. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009, 19:230-236.
95. Laux D., Kratz C., Sauerbrey A. Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome. J Pediatr Hematol Oncol 2008, 30:602-604.
96. Gutmann D.H., Aylsworth A., Carey J.C., et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51-57.
97. Bader J.L., Miller R.W. Neurofibromatosis and childhood leukemia. J Pediatr 1978, 92:925-929.
98. Brems H., Beert E., de Ravel T., et al. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 2009, 10:508-515.
99. Williams V.C., Lucas J., Babcock M.A., et al. Neurofibromatosis type 1 revisited. Pediatrics 2009, 123:124-133.
100. Ferner R.E. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 2007, 6:340-351.
101. Luna-Fineman S., Shannon K.M., Lange B.J. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood 1995, 85:1985-1999.
102. Maris J.M., Wiersma S.R., Mahgoub N., et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 1997, 79:1438-1446.
103. Cawthon R.M., Weiss R., Xu G.F., et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990, 62:193-201.
104. Viskochil D., Buchberg A.M., Xu G., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990, 62:187-192.
105. Wallace M.R., Marchuk D.A., Andersen L.B., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249:181-186.
106. Thomson S.A., Fishbein L., Wallace M.R. NF1 mutations and molecular testing. J Child Neurol 2002, 17:555-561.
107. Bollag G., Clapp D.W., Shih S., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996, 12:144-148.
108. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308.
109. Messiaen L.M., Callens T., Mortier G., et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000, 15:541-555.
110. Wimmer K., Yao S., Claes K., et al. Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer 2006, 45:265-276.
111. Kayes L.M., Burke W., Riccardi V.M., et al. Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am J Hum Genet 1994, 54:424-436.
112. Kluwe L., Siebert R., Gesk S., et al. Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 2004, 23:111-116.
113. Upadhyaya M., Huson S.M., Davies M., et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 2007, 80:140-151.
114. Cambiaghi S., Restano L., Caputo R. Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies. Pediatr Dermatol 2004, 21:97-101.
115. Shannon K.M., O'Connell P., Martin G.A., et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994, 330:597-601.
116. Side L.E., Shannon K.M. The NF1 gene as a tumor suppressor. Neurofibromatosis Type 1 1998, 133-152. Bios Scientific Publishers, Oxford, UK. M. Upashyaya, D.N. Cooper (Eds.).
117. Stephens K., Weaver M., Leppig K.A., et al. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood 2006, 108:1684-1689.
118. Mendez H.M., Opitz J.M. Noonan syndrome: a review. Am J Med Genet 1985, 21:493-506.
119. Nora J.J., Nora A.H., Sinha A.K., et al. The Ullrich-Noonan syndrome (Turner phenotype). Am J Dis Child 1974, 127:48-55.
120. Jongmans M., Sistermans E.A., Rikken A., et al. Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. Am J Med Genet A 2005, 134A:165-170.
121. Tartaglia M., Gelb B.D. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 2005, 6:45-68.
122. Allanson JE. Noonan syndrome. GeneReviews, 1993-. Available at: . Accessed on March 15, 2011. http://www.ncbi.nlm.nih.gov/books/NBK1124.
123. Denayer E., Devriendt K., de Ravel T., et al. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations. Genes Chromosomes Cancer 2010, 49:242-252.
124. Jorge A.A., Malaquias A.C., Arnhold I.J., et al. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway. Horm Res 2009, 71:185-193.
125. Marino B., Digilio M.C., Toscano A., et al. Congenital heart diseases in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 1999, 135:703-706.
126. Bertola D.R., Carneiro J.D., D'Amico E.A., et al. Hematological findings in Noonan syndrome. Rev Hosp Clin Fac Med Sao Paulo 2003, 58:5-8.
127. Witt D.R., McGillivray B.C., Allanson J.E., et al. Bleeding diathesis in Noonan syndrome: a common association. Am J Med Genet 1988, 31:305-317.
128. Bader-Meunier B., Tchernia G., Mielot F., et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 1997, 130:885-889.
129. Choong K., Freedman M.H., Chitayat D., et al. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 1999, 21:523-527.
130. Kratz C.P., Niemeyer C.M., Castleberry R.P., et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005, 106:2183-2185.
131. Niihori T., Aoki Y., Ohashi H., et al. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet 2005, 50:192-202.
132. Niemeyer C.M., Kang M.W., Shin D.H., et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010.
133. Feng G.S. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res 1999, 253:47-54.
134. Van Vactor D., O'Reilly A.M., Neel B.G. Genetic analysis of protein tyrosine phosphatases. Curr Opin Genet Dev 1998, 8:112-126.
135. Loh M.L., Vattikuti S., Schubbert S., et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004, 103:2325-2331.
136. Tartaglia M., Niemeyer C.M., Fragale A., et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003, 34:148-150.
137. Grossmann K.S., Rosario M., Birchmeier C., et al. The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res 2010, 106:53-89.
138. Barford D., Neel B.G. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 1998, 6:249-254.
139. Neel B.G., Gu H., Pao L. The " Shp" ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003, 28:284-293.
140. Chen B., Bronson R.T., Klaman L.D., et al. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet 2000, 24:296-299.
141. Carta C., Pantaleoni F., Bocchinfuso G., et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 2006, 79:129-135.
142. Martinelli S., De Luca A., Stellacci E., et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 2010, 87:250-257.
143. Roberts A.E., Araki T., Swanson K.D., et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007, 39:70-74.
144. Schubbert S., Zenker M., Rowe S.L., et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006, 38:331-336.
145. Tartaglia M., Pennacchio L.A., Zhao C., et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007, 39:75-79.
146. Perez B., Mechinaud F., Galambrun C., et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet 2010, 47:686-691.
147. Tartaglia M., Martinelli S., Stella L., et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 2006, 78:279-290.
148. Loh M.L., Sakai D.S., Flotho C., et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009, 114:1859-1863.
149. Zenker M. Genetic and pathogenetic aspects of Noonan syndrome and related disorders. Horm Res 2009, 72(Suppl 2):57-63.
150. Zeidler C., Welte K. Kostmann syndrome and severe congenital neutropenia. Semin Hematol 2002, 39:82-88.
151. Welte K., Zeidler C. Severe congenital neutropenia. Hematol Oncol Clin North Am 2009, 23:307-320.
152. Kostmann R. Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. Acta Paediatr Suppl 1956, 45:1-78.
153. Boztug K., Appaswamy G., Ashikov A., et al. A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med 2009, 360:32-43.
154. Germeshausen M., Grudzien M., Zeidler C., et al. Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations. Blood 2008, 111:4954-4957.
155. Dale DC. ELANE-related neutropenia. GeneReviews, 1993-. Available at: . Accessed on March 27, 2011. http://www.ncbi.nlm.nih.gov/books/NBK1533/.
156. Klein C., Grudzien M., Appaswamy G., et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007, 39:86-92.
157. Boxer L.A., Stein S., Buckley D., et al. Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations. J Pediatr 2006, 148:633-636.
158. Dale D.C., Person R.E., Bolyard A.A., et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000, 96:2317-2322.
159. Freedman M.H., Bonilla M.A., Fier C., et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000, 96:429-436.
160. Hunter M.G., Avalos B.R. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. Blood 2000, 95:2132-2137.
161. Rosenberg P.S., Zeidler C., Bolyard A.A., et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010, 150:196-199.
162. Rosenberg P.S., Alter B.P., Bolyard A.A., et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006, 107:4628-4635.
163. Beekman R., Touw I.P. G-CSF and its receptor in myeloid malignancy. Blood 2010, 115:5131-5136.
164. Bux J., Behrens G., Jaeger G., et al. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998, 91:181-186.
165. Dale D.C., Liles W.C., Garwicz D., et al. Clinical implications of mutations of neutrophil elastase in congenital and cyclic neutropenia. J Pediatr Hematol Oncol 2001, 23:208-210.
166. Horwitz M.S., Duan Z., Korkmaz B., et al. Neutrophil elastase in cyclic and severe congenital neutropenia. Blood 2007, 109:1817-1824.
167. Grenda D.S., Murakami M., Ghatak J., et al. Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis. Blood 2007, 110:4179-4187.
168. Kollner I., Sodeik B., Schreek S., et al. Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response. Blood 2006, 108:493-500.
169. Germeshausen M., Ballmaier M., Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood 2007, 109:93-99.
170. Zeidler C., Germeshausen M., Klein C., et al. Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. British Journal of Haematology 2009, 144:459-467.
171. Bonilla M.A., Gillio A.P., Ruggeiro M., et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 1989, 320:1574-1580.
172. Dale D.C., Bonilla M.A., Davis M.W., et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993, 81:2496-2502.
173. Welte K., Boxer L.A. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol 1997, 34:267-278.
174. Elhasid R., Rowe J.M. Hematopoetic stem cell transplantation in neutrophil disorders: severe congenital neutropenia, leukocyte adhesion deficiency and chronic granulomatous disease. Clin Rev Allergy Immunol 2010, 38:61-67.
175. Zeidler C., Welte K., Barak Y., et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 2000, 95:1195-1198.
176. Choi S.W., Boxer L.A., Pulsipher M.A., et al. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant 2005, 35:473-477.
177. Owen C.J., Toze C.L., Koochin A., et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008, 112:4639-4645.
178. Preudhomme C., Renneville A., Bourdon V., et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 2009, 113:5583-5587.
179. Jongmans M.C., Kuiper R.P., Carmichael C.L., et al. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. Leukemia 2010, 24:242-246.
180. Owen C., Barnett M., Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia-a review. Br J Haematol 2008, 140:123-132.
181. Ganly P., Walker L.C., Morris C.M. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia. Leuk Lymphoma 2004, 45:1-10.
182. Walker L.C., Stevens J., Campbell H., et al. A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia. Br J Haematol 2002, 117:878-881.
183. Nishimoto N., Imai Y., Ueda K., et al. T cell acute lymphoblastic leukemia arising from familial platelet disorder. Int J Hematol 2010, 92:194-197.
184. Song W.J., Sullivan M.G., Legare R.D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999, 23:166-175.
185. Michaud J., Simpson K.M., Escher R., et al. Integrative analysis of RUNX1 downstream pathways and target genes. BMC Genomics 2008, 9:363.
186. Cohen M.M. Perspectives on RUNX genes: an update. Am J Med Genet A 2009, 149A:2629-2646.
187. Kumano K., Kurokawa M. The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells. J Cell Physiol 2010, 222:282-285.
188. Michaud J., Wu F., Osato M., et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002, 99:1364-1372.
189. Heller P.G., Glembotsky A.C., Gandhi M.J., et al. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood 2005, 105:4664-4670.
190. Osato M., Ito Y. Increased dosage of the RUNX1/AML1 gene: a third mode of RUNX leukemia?. Crit Rev Eukaryot Gene Expr 2005, 15:217-228.
191. Dicker F., Haferlach C., Sundermann J., et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010.
192. Buijs A., Poddighe P., van Wijk R., et al. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood 2001, 98:2856-2858.
193. Nanri T., Uike N., Kawakita T., et al. A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation. Genes Chromosomes Cancer 2010, 49:237-241.
194. Pabst T., Eyholzer M., Haefliger S., et al. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008, 26:5088-5093.
195. Renneville A., Mialou V., Philippe N., et al. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 2009, 23:804-806.
196. Sellick G.S., Spendlove H.E., Catovsky D., et al. Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 2005, 19:1276-1278.
197. Smith M.L., Cavenagh J.D., Lister T.A., et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004, 351:2403-2407.
198. Fuchs O., Provaznikova D., Kocova M., et al. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Mol Dis 2008, 40:401-405.
199. Manola K.N., Sambani C., Karakasis D., et al. Leukemias associated with Turner syndrome: report of three cases and review of the literature. Leuk Res 2008, 32:481-486.
200. Patroglu T., Torun Y.A., Karakukcu M., et al. A case of Turner syndrome associated with acute myeloid leukemia (M2). J Pediatr Hematol Oncol 2006, 28:682-683.
201. Abruzzese E., Rao P.N., Slatkoff M., et al. Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases. Cancer Genet Cytogenet 1997, 93:140-146.
202. Maserati E., Aprili F., Vinante F., et al. Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. Genes Chromosomes Cancer 2002, 33:93-97.
203. Brady A.F., Waters C.S., Pocha M.J., et al. Chronic myelomonocytic leukaemia in a child with constitutional partial trisomy 8 mosaicism. Clin Genet 2000, 58:142-146.
204. Yamamoto K., Okamura A., Kawano H., et al. A novel t(8;18)(q13;q21) in acute monocytic leukemia evolving from constitutional trisomy 8 mosaicism. Cancer Genet Cytogenet 2007, 176:144-149.
205. Hasle H., Clausen N., Pedersen B., et al. Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype. Cancer Genet Cytogenet 1995, 79:79-81.
206. Narendran A., Hawkins L.M., Ganjavi H., et al. Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr Hematol Oncol 2004, 21:209-221.
207. Seghezzi L., Maserati E., Minelli A., et al. Constitutional trisomy 8 as first mutation in multistep carcinogenesis: clinical, cytogenetic, and molecular data on three cases. Genes Chromosomes Cancer 1996, 17:94-101.
208. Frey N.V., Leid C.E., Nowell P.C., et al. Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality. Am J Hematol 2008, 83:846-849.
209. Malinge S., Izraeli S., Crispino J.D. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009, 113:2619-2628.
210. Brewster H., Cannon H. Acute lymphatic leukemia: report of case in eleventh month mongolian idiot. New Orleans Medical Surgery Journal 1930, 82:872-873.
211. Online Mendelian Inheritance in Man (OMIM). Down syndrome. 1994-. Available at: . Accessed on April 21, 2011. http://www.ncbi.nlm.nih.gov/omim.
212. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000, 110:512-524.
213. Fonatsch C. The role of chromosome 21 in hematology and oncology. Genes Chromosomes Cancer 2010, 49:497-508.
214. Hitzler J.K. Acute megakaryoblastic leukemia in Down syndrome. Pediatr Blood Cancer 2007, 49:1066-1069.
215. Massey G.V., Zipursky A., Chang M.N., et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006, 107:4606-4613.
216. Kacena MA, Chou ST, Weiss MJ, et al. GATA1-related X-linked cytopenia. GeneReviews, 1993-. Available at: . Accessed on April 19, 2011. http://www.ncbi.nlm.nih.gov/books/NBK1364/.
217. Shimizu R., Engel J.D., Yamamoto M. GATA1-related leukaemias. Nat Rev Cancer 2008, 8:279-287.
218. Hollanda L.M., Lima C.S., Cunha A.F., et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 2006, 38:807-812.
219. Kanezaki R., Toki T., Terui K., et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood 2010, 116:4631-4638.
220. Potocki L., Townes P.L., Woda B.A., et al. Tetrasomy 21 in megakaryoblastic leukemia. Cancer Genet Cytogenet 1994, 74:66-70.
221. Roy A., Roberts I., Norton A., et al. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br J Haematol 2009, 147:3-12.
222. Yamaguchi Y., Fujii H., Kazama H., et al. Acute myeloblastic leukemia associated with trisomy 8 and translocation 8;21 in a child with Down syndrome. Cancer Genet Cytogenet 1997, 97:32-34.
223. Hama A., Yagasaki H., Takahashi Y., et al. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. Br J Haematol 2008, 140:552-561.
224. Shah N., Al-Ahmari A., Al-Yamani A., et al. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer 2009, 52:14-19.
225. Whitlock J.A., Sather H.N., Gaynon P., et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2005, 106:4043-4049.
226. Maloney K.W., Carroll W.L., Carroll A.J., et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 2010, 116:1045-1050.
227. Whitlock J.A. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006, 135:595-602.
228. Bercovich D., Ganmore I., Scott L.M., et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372:1484-1492.
229. Gaikwad A., Rye C.L., Devidas M., et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009, 144:930-932.
230. Hertzberg L., Vendramini E., Ganmore I., et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115:1006-1017.
231. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
232. Goto H., Inukai T., Inoue H., et al. Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group. Int J Hematol 2011, 93:192-198.
233. Chan R.J., Cooper T., Kratz C.P., et al. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leukemia Research 2009, 33:355-362.
234. Nagy R., Sweet K., Eng C. Highly penetrant hereditary cancer syndromes. Oncogene 2004, 23:6445-6470.
235. Kutler D.I., Auerbach A.D. Fanconi anemia in Ashkenazi Jews. Familial Cancer 2004, 3:241-248.
236. Auerbach A.D. Fanconi anemia and its diagnosis. Mutat Res 2009, 668:4-10.
237. Drabek J., Hajduch M., Gojova L., et al. Frequency of 657del(5) mutation of the NBS1 gene in the Czech population by polymerase chain reaction with sequence specific primers. Cancer Genet Cytogenet 2002, 138:157-159.
238. Li L., Eng C., Desnick R.J., et al. Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population. Mol Genet Metab 1998, 64:286-290.